АНТИКОАГУЛЯЦИЯ ПРИ ЗАМЕСТИТЕЛЬНОЙ ПОЧЕЧНОЙ ТЕРАПИИ: КЛАССИЧЕСКИЕ ПОДХОДЫ И НОВЫЕ ВОЗМОЖНОСТИ
https://doi.org/10.15825/1995-1191-2010-4-80-85
Аннотация
Применение антикоагулянтов является одним из ключевых моментов при заместительной почечной те- рапии. В данном обзоре литературы рассмотрены традиционная гепаринизация и ее осложнения, низко- молекулярные гепарины, широко применяющиеся в программном гемодиализе, безгепариновый диализ, регионарная цитратная антикоагуляция, а также современные альтернативные антикоагулянты.
Ключевые слова
Об авторах
А. Г. Строков
ФГУ «Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздравсоцразвития РФ, Москва
Россия
Россия
Я. Л. Поз
ФГУ «Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздравсоцразвития РФ, Москва
Россия
Россия
Список литературы
1. Шило В.Ю. Низкомолекулярные гепарины в гемоди- ализе: многолетний опыт применения далтепарина // Клиницист. 2008. Vol. 2. P. 55–61.
2. Bagshaw S.M., Laupland K.B., Boiteau P.J., Godinez- Luna T. Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement thera- py? A prospective observational study in an adult regi- onal critical care system // J. Crit. Care. 2005. Vol. 20. P. 155–161.
3. Bakker A.J., Boerma E.C., Keidel H., Kingma P., van der Voort P.H. Detection of citrate overdose in critically ill patients on citrate-anticoagulated venovenous haemofil- tration: use of ionised and total/ionised calcium // Clin. Chem. Lab. Med. 2006. Vol. 44. P. 962–966.
4. Bernieh B., Boobes Y., Al Hakim M.R. et al. Long-term use of low-molecular-weight heparin in hemodialy- sis patients: a 7-year experience // Blood Purif. 2009. Vol. 27 (3). P. 242–245.
5. Brunet P., Simon N., Opris A. et al. Pharmacodynamics of unfractionated heparin during and after a hemodi- alysis session // Am. J. Kidney Dis. 2008. Vol. 51 (5). P. 789–795.
6. Burry L.D., Tung D.D., Hallett D. et al. Regional citrate anticoagulation for PrismaFlex continuous renal repla- cement therapy // Ann Pharmacother. 2009. Vol. 43 (9). P. 1419–1425.
7. Chanard J., Lavaud S., Maheut H. et al. The clinical evaluation of low-dose heparin in haemodialysis: a pro- spective study using the heparin-coated AN69 ST mem- brane // Nephrol. Dial. Transplant. 2008. Vol. 23 (6). P. 2003–2009.
8. Chanard J., Lavaud S., Randoux C., Rieu P. New in- sights in dialysis membrane biocompatibility: relevance of adsorption properties and heparin binding // Nephrol. Dial. Transplant. 2003. Vol. 18. P. 252–257.
9. Charif R., Davenport A. Heparin-induced thrombocy- topenia: An uncommon but serious complication of he- parin use in renal replacement therapy // Hemodial. Int. 2006. Vol. 10. P. 235–240.
10. Davenport A. Review article: Low-molecular-weight heparin as an alternative anticoagulant to unfractiona- ted heparin for routine outpatient haemodialysis treat- ments // Nephrology. 2009. Vol. 14. P. 455–461.
11. Douketis J., Cook D., Meade M. et al. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular- weight heparin dalteparin. An assessment of safety and pharmacodynamics: the DIRECT study // Arch Intern Med. 2008. Vol. 168 (16). P. 1805–1812.
12. European Best Practice Guidelines // Nephrol. Dial. Transplant. 2002. Vol. 17 (Suppl. 7). P. 63.
13. Evenepoel P., Dejagere T., Verhamme P. et al. Heparin- coated polyacrylonitrile membrane versus regional citrate anticoagulation: a prospective randomized study of 2 anticoagulation strategies in patients at risk of blee- ding // Am. J. Kidney Dis. 2007. Vol. 49 (5). P. 642–649.
14. Frank R.D., Müller U., Lanzmich R. et al. Anticoagulant- free Genius haemodialysis using low molecular weight heparin-coated circuits // Nephrol. Dial. Transplant. 2006. Vol. 21 (4). P. 1013–1018.
15. Geerts W.H., Bergqvist D., Pineo G.F. et al. Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines (8th Edition) // Chest. 2008. Vol. 133. S. 381–453.
16. Greaves M. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Com- mittee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis // Thromb. Haemost. 2002. Vol. 87. P. 163–164.
17. Hursting M.J., Murray P.T. Argatroban anticoagulation in renal dysfunction: a literature analysis // Nephron. Clin. Pract. 2008. Vol. 109 (2). P. 80–94.
18. Kalicki R.M., Aregger F., Alberio L. et al. Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis // Thromb. Haemost. 2007. Vol. 98 (6). P. 1200–1207.
19. Kodras K., Benesch T., Neumann I., Haas M. Compa- rison of two dialysers (AN69ST vs. FX100) for hepa- rin-free dialysis in patients with oral anticoagulation // Blood Purif. 2008. Vol. 26 (3). P. 226–230.
20. Kozik-Jaromin J., Nier V., Heemann U. et al. Citrate pharmacokinetics and calcium levels during high-flux dialysis with regional citrate anticoagulation // Nephrol. Dial. Transplant. 2009. Vol. 24 (7). P. 2244–2251.
21. Lai K.N., Ho K., Cheung R.C. et al. Effect of low mole- cular weight heparin on bone metabolism and hyperlipi- daemia in patients on maintenance haemodialysis // Int. J. Artif. Organs. 2001. Vol. 24. P. 447–455.
22. Lim W., Cook D.J., Crowther M.A. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials // J. Am. Soc. Nephrol. 2004. Vol. 15. P. 3192–3206.
23. Lobo B.L. Use of newer anticoagulants in patients with chronic kidney disease // Am. J. Health Syst. Pharm. 2007. Vol. 64 (19). P. 2017–2026.
24. Martel N., Lee J., Wells P.S. Risk for heparin-induced thrombocytopenia with unfractionated heparin and low-
25. molecular-weight heparin thromboprophylaxis: a meta-
26. analysis // Blood. 2005. Vol. 106. P. 2710–2715.
27. Matsuo T., Wanaka K. Management of uremic pati- ents with heparin-induced thrombocytopenia requiring hemodialysis // Clin. Appl. Thromb. Hemost. 2008. Vol. 14 (4). P. 459–464.
28. Morgera S., Schneider M., Slowinski T. et al. A safe citrate anticoagulation protocol with variable treatment ef- ficacy and excellent control of the acid-base status // Crit Care Med. 2009. Vol. 37 (6). P. 2018–2024.
29. Oudemans-van Straaten H.M., Wester J.P., de Pont A.C., Schetz M.R. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? // Intensive Care Med. 2006. Vol. 32. P. 188– 202.
30. Perry S.L., O’Shea S.I., Byrne S. et al. A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients // Thromb. Haemost. 2006. Vol. 96 (6). P. 750– 755.
31. Schmid P., Broadmann D., Fischer A.G., Wuillemin W.A. Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function // J. Thromb. Haemost. 2009. Vol. 7 (4). P. 552– 558.
32. Stegmayr B., Olivecrona T., Olivecrona G. Lipoprotein lipase disturbances induced by uremia and hemodialy- sis // Semin Dial. 2009. Vol. 22 (4). P. 442–444.
33. Uchino S., Bellomo R., Morimatsu H. et al. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators // Intensive Care Med. 2007. Vol. 33 (9). P. 1563–1570.
34. Uchino S., Fealy N., Baldwin I., Morimatsu H., Bello- mo R. Continuous venovenous hemofiltration without anticoagulation // ASAIO J. 2004. Vol. 50. P. 76–80.
35. Vanholder R., Dhondt A. Recombinant hirudin: clinical pharmacology and potential applications in nephrolo- gy // BioDrugs. 1999. Vol. 11 (6). P. 417–429.
36. Vitale C., Verdecchia C., Bagnis C. et al. Effects of der- matan sulfate for anticoagulation in continuous renal replacement therapy // J. Nephrol. 2008. Vol. 21 (2). P. 205–212.
37. Wiemer J., Winkler K., Baumstark M. et al. Influence of low molecular weight heparin compared to conventional heparin for anticoagulation during haemodialysis on low density lipoprotein subclasses // Nephrol. Dial. Trans- plant. 2002. Vol. 17. P. 2231–2238.
Рецензия
Для цитирования:
Строков А.Г., Поз Я.Л. АНТИКОАГУЛЯЦИЯ ПРИ ЗАМЕСТИТЕЛЬНОЙ ПОЧЕЧНОЙ ТЕРАПИИ: КЛАССИЧЕСКИЕ ПОДХОДЫ И НОВЫЕ ВОЗМОЖНОСТИ. Вестник трансплантологии и искусственных органов. 2010;12(4):80-85. https://doi.org/10.15825/1995-1191-2010-4-80-85
For citation:
Strokov A.G., Poz Y.L. CLOTTING PREVENTION IN RENAL REPLACEMENT THERAPY: CLASSICAL APPROACHES AND NEW OPPORTUNITIES. Russian Journal of Transplantology and Artificial Organs. 2010;12(4):80-85. (In Russ.) https://doi.org/10.15825/1995-1191-2010-4-80-85
Просмотров: 1034
Послать статью по эл. почте 